This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.

This study has been terminated.
(Primary endpoint measure not suitable for evaluation)
Information provided by (Responsible Party):
Copenhagen University Hospital at Herlev Identifier:
First received: August 29, 2008
Last updated: June 18, 2014
Last verified: June 2014
By applying short electric pulses to cells, the cell membranes can become permeabilised (electroporation). This can be used augment the effect of chemotherapy, by providing direct access to the cell cytosol. For the drug bleomycin, the enhancement of effect is several hundred fold, enabling once-only treatment. We wish to offer electrochemotherapy to breast cancer patients suffering from chest wall recurrences that are ulcerated or painful and where other treatments have failed.

Condition Intervention Phase
Breast Cancer Procedure: Electrochemotherapy Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects.

Resource links provided by NLM:

Further study details as provided by Copenhagen University Hospital at Herlev:

Primary Outcome Measures:
  • Clinical Measure of Lesion Size. [ Time Frame: up to one year ]
    Response was evaluated clinical using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines and documented with digital photography. Number of patients with objective response evaluated with clinical measure of lesion size

Secondary Outcome Measures:
  • Participants With Objective Response Evaluated With PET/CT [ Time Frame: 3, weeks, 8 weeks, and up to 6 months after treatment ]
    Participants with objective response evaluated with PET/CT. Objective Response evaluated with CT and PET/CT.

  • Safety and Toxicity [ Time Frame: up to 1 year ]

Enrollment: 17
Study Start Date: October 2008
Study Completion Date: December 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Patients with local-regional recurrence of breast cancer, lesion over 3 cm.
Procedure: Electrochemotherapy
Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
Other Names:
  • Device: Cliniporator
  • Drug: Bleomycin

Detailed Description:

Electrochemotherapy for chest wall recurrence of breast cancer. MD, Ph.D. student, Louise Wichmann Matthiessen, has been employed in 2008 to perform this study. She plans to complete her training as specialist in clinical oncology subsequently, and will thus be able to follow up the work after completion of her Ph.D. The study aims at giving palliation to patients who are suffering from painful, ulcerated metastases to the chest wall in a situation where other treatments have failed.

Inclusion criteria: Chest wall recurrence of breast cancer; all other modalities have failed or patients does not wish to receive them (e.g. chemotherapy); symptomatic relief is needed; WHO performance status 0-2; normal coagulation parameters, normal kidney and renal function; written, informed consent. Lesions totalling over 3 cm in diameter. Patient recruitment: 28 patients are to be recruited.

Treatment: Patients will be treated in general anesthesia (inhaling max. 30 % oxygen), and a standard dose of bleomycin (15.000 IU/ m2) will be given intravenously. Electric pulses will be administered using a square wave electroporator (IGEA, Carpi, Italy). Needle and plate electrodes are used in order to treat the affected area efficiently. Eight pulses at a frequency of 5 kHz will be used for each application of the electrodes. In this way, a large area can be treated within a short time. Post treatment, the area will be covered by dry dressings, as are standardly used.

The patients will be seen at 2, 4, and 8 weeks post treatment, and re-treatment can be administered up to three times in case there are areas which have not been insufficiently treated in the first round. Lung function will be followed by measurement of DLCO (carbon monoxide diffusion capacity).

The patients will furthermore be followed up to 1 year after treatment in monthly intervals, and after 1 year on a yearly basis for up to 5 years.

Evaluation: Evaluation is performed by a) measurement of lesion extension and digital photography, b) development of a mapping system: Chest wall recurrences are frequently a confluent mass of tumor with varying depth. Precise mapping of treatment areas and effect is warranted. To this end, a system combining a fixed point (e.g. small ink tattoo, as used in radiotherapy planning) with novel imaging techniques using the 3D computer tomography (CT) planning system employed for radiotherapy, is envisaged. Furthermore, PET-Dual Time Point scanning combined with CT scanning is being investigated as treatment evaluation.

Safety: Safety will be reported both in terms of evaluation of adverse events and in terms of patient satisfaction determined by questionnaire, including the 'Derriford Appearance Questionaire'(18).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 18
  • Histological proven cancer of the breast.
  • Progressive and/or metastatic disease.
  • No further standard treatment for the patient available or the patient does not wish to receive the offered standard treatment.
  • If Endocrine therapy: Progression in cutaneous lesions.
  • If treatment with trastuzumab (Herceptin)can continue this treatment if there is no regression in cutaneous lesions.
  • At least 2 weeks since last chemotherapy, patients treated with Navelbine (Vinorelbine), Capecitabin (Xeloda) or weekly Paclitaxel (Taxol)can continue this treatment if there is no regression in cutaneous metastases.
  • Malignant cutaneous or subcutaneous lesion to be treated ≥ 3 cm.
  • WHO performance ≤ 2.
  • Life expectancy of at least 3 months.
  • Platelets ≥ 50 mia/l, pp ≥ 40, APTT in normal area. Medical correction is allowed.
  • Sexual active men and women must use safe anticonceptive during and up to 6 month after last treatment.
  • Written informed consent must be obtained according to the local Ethics committee requirements.

Exclusion Criteria:

  • Acute lung infection
  • Previous bleomycin treatment exceeding 200.000 Units/m2.
  • Known hypersensitivity to any of the components of the treatment.
  • Known hypersensitivity to any of the components used in the planned anesthesia.
  • Pregnant or lactating women. In fertile women this is ensured by measuring HCG in blood.
  • Treatment with granulocyte colony stimulating factor (G-CSF) or other cytokines.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00744653

Herlev Hospital, Herlev Ringvej 75
Herlev, Denmark, DK-2730
Sponsors and Collaborators
Copenhagen University Hospital at Herlev
Principal Investigator: Julie Gehl, M.D. Department of Oncology, Copenhagen University Hospital at Herlev
  More Information

Responsible Party: Copenhagen University Hospital at Herlev Identifier: NCT00744653     History of Changes
Other Study ID Numbers: H-B-2008-074
Study First Received: August 29, 2008
Results First Received: March 22, 2011
Last Updated: June 18, 2014

Keywords provided by Copenhagen University Hospital at Herlev:
Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Disease Attributes
Pathologic Processes
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on September 21, 2017